• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gh Research Plc (NQ: GHRS )

    8.830 +0.730 (+9.01%)
    Streaming Delayed Price Updated: 11:52 AM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Gh Research Plc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
    The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
    Via Talk Markets
    Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
    While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
    Via Talk Markets
    Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
    The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
    Via Talk Markets
    Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
    Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and... 
    Via Benzinga
    Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
    Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
    Via Talk Markets
    GH Research: Q4 Earnings Insights
    Via Benzinga
    Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
    This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
    Via Talk Markets
    3 Psychedelic Stocks to Ride to the Moon and Beyond
    Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market. 
    Via InvestorPlace
    Exposures Product Safety
    Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
    Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks. 
    Via InvestorPlace
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
    Via Talk Markets
    Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
    Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
    Via Talk Markets
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
    This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
    Via Talk Markets
    Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
    We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
    Via Talk Markets
    GHRS Stock Earnings: GH Research Beats EPS for Q1 2024
    GHRS stock results show that GH Research beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
    A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
    Via Talk Markets
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
    The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD. 
    Via Talk Markets
    March Recap: Largest Psychedelic Drug Stocks Up Another 5%
    The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD. 
    Via Talk Markets
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
    The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder. 
    Via Talk Markets
    Exposures Product Safety
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
    Via Benzinga
    Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
    The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%. 
    Via Talk Markets
    GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
    Via Benzinga
    Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
    IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking... 
    Via Talk Markets
    Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
    Via Benzinga
    5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
    The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. 
    Via Talk Markets
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.